Browsing by Author Iser, David M.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2017Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 ` final results of the REV1TAL studyGeorge, Jacob; Bollipo, Steven; Chivers, Sarah; Dore, Gregory J.; et al, Various; Fragomeli, Vincenzo; Gow, Paul J; Iser, David M.; Jones, Tracey L.; Levy, Miriam; Lubel, John; Mitchell, Joanne L.; Pianko, Stephen; Strasser, S; Stuart, Katherine Anne; Thompson, Alexander James V.; Westmead Clinical School: Westmead Institute for Medical ResReal-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 ` final results of the REV1TAL study, Antiviral Therapy, vol.22, 8, 2017,pp 699-710
2016Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studiesHaber, Paul; Applegate, Tanya; Dore, Gregory J.; Grebely, Jason; Hellard, Margaret; Iser, David M.; Lloyd, Andrew; Maire, Laurence; Martinello, Marianne; Matthews, Gail; Petoumenos, Kathy; Sasadeusz, J; Shaw, David R; Thompson, Alexander; Yeung, Barbara; Central Clinical School: Addiction MedicineShort duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies, Antiviral Therapy, vol.21, 5, 2016,pp 425-434
2016Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studiesHaber, Paul; Applegate, Tanya; Dore, Gregory J.; Grebely, Jason; Hellard, Margaret; Iser, David M.; Lloyd, Andrew; Maire, Laurence; Martinello, Marianne; Matthews, Gail; Petoumenos, Kathy; Sasadeusz, J; Shaw, David R; Thompson, Alexander; Yeung, Barbara; Central Clinical School: Addiction MedicineShort duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies, Antiviral Therapy, vol.21, 5, 2016,pp 425-434